Xiaobing Le

640 total citations
11 papers, 163 citations indexed

About

Xiaobing Le is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Xiaobing Le has authored 11 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cancer Research, 7 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Xiaobing Le's work include RNA modifications and cancer (5 papers), Cancer-related molecular mechanisms research (5 papers) and Lung Cancer Treatments and Mutations (3 papers). Xiaobing Le is often cited by papers focused on RNA modifications and cancer (5 papers), Cancer-related molecular mechanisms research (5 papers) and Lung Cancer Treatments and Mutations (3 papers). Xiaobing Le collaborates with scholars based in China, United States and Spain. Xiaobing Le's co-authors include Xiaoshun Shi, Shengtao Zhou, Lian Xu, Wayne Bond Lau, Allen Chen, Linjie Zhao, Bonnie Lau, Qilian Yang, Tao Yi and Xia Zhao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Oncotarget.

In The Last Decade

Xiaobing Le

9 papers receiving 163 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaobing Le China 5 82 69 67 46 34 11 163
Anna Karlsson Sweden 6 110 1.3× 42 0.6× 65 1.0× 36 0.8× 11 0.3× 9 159
Siti Norhidayu Hasan Malaysia 3 46 0.6× 66 1.0× 64 1.0× 24 0.5× 26 0.8× 7 117
Yuehong Yang Finland 5 94 1.1× 42 0.6× 27 0.4× 64 1.4× 54 1.6× 8 171
Zachary C. Fogarty United States 9 139 1.7× 96 1.4× 29 0.4× 55 1.2× 70 2.1× 22 251
Dianna Hussmann Denmark 6 125 1.5× 35 0.5× 80 1.2× 65 1.4× 17 0.5× 8 196
Chun-Lin Lin United States 8 205 2.5× 127 1.8× 78 1.2× 68 1.5× 17 0.5× 9 287
Lise M. van Wijk Netherlands 4 98 1.2× 35 0.5× 112 1.7× 19 0.4× 37 1.1× 5 192
Sonia Fernández‐Ruiz Spain 5 111 1.4× 61 0.9× 40 0.6× 28 0.6× 16 0.5× 6 167
Laura P. Brandt Switzerland 5 147 1.8× 57 0.8× 49 0.7× 86 1.9× 29 0.9× 6 192
Daliah Tsoref Israel 6 66 0.8× 33 0.5× 59 0.9× 23 0.5× 41 1.2× 15 166

Countries citing papers authored by Xiaobing Le

Since Specialization
Citations

This map shows the geographic impact of Xiaobing Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobing Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobing Le more than expected).

Fields of papers citing papers by Xiaobing Le

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobing Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobing Le. The network helps show where Xiaobing Le may publish in the future.

Co-authorship network of co-authors of Xiaobing Le

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobing Le. A scholar is included among the top collaborators of Xiaobing Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobing Le. Xiaobing Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Ferrara, Roberto, Xiaobing Le, Hiroya Sakai, et al.. (2025). 81P: Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes. Journal of Thoracic Oncology. 20(3). S59–S60.
3.
Felip, Enriqueta, V. Minotti, Julius Wolf, et al.. (2021). P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S585–S586. 4 indexed citations
4.
Shi, Xiaoshun, et al.. (2019). MicroRNA-550a is associated with muscle system conferring poorer survival for esophageal cancer. Bioscience Reports. 39(5). 1 indexed citations
5.
Zhao, Linjie, Shuang Huang, Shenglin Mei, et al.. (2018). Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proceedings of the National Academy of Sciences. 115(16). E3673–E3681. 60 indexed citations
6.
Shi, Xiaoshun, Xiaobing Le, Xiaoxiang Li, et al.. (2018). An expression signature model to predict lung adenocarcinoma-specific survival. Cancer Management and Research. Volume 10. 3717–3732. 32 indexed citations
7.
Shi, Xiaoshun, Allen Chen, Xiaobing Le, et al.. (2017). LncRNA TUSC7 affects malignant tumor prognosis by regulating protein ubiquitination: a genome-wide analysis from 10,237 pan-cancer patients. Translational Cancer Research. 6(4). 834–842. 1 indexed citations
8.
Shi, Xiaoshun, Fuxi Huang, Xiaobing Le, et al.. (2017). A practical prognostic lncRNA signature for lung squamous cell carcinoma. SHILAP Revista de lepidopterología. 2(1). 3 indexed citations
9.
Li, Jin, Yaoqi Chen, Xiaoshun Shi, et al.. (2017). A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. Journal of Thoracic Disease. 9(8). 2560–2571. 28 indexed citations
10.
Shi, Xiaoshun, Allen Chen, Xiaobing Le, et al.. (2017). LncRNA TUSC7 affects malignant tumor prognosis by regulating protein ubiquitination: a genome-wide analysis from 10,237 pan-cancer patients. Translational Cancer Research. 6(4). 834–842. 2 indexed citations
11.
Yang, Yanfei, Linjie Zhao, Lingzi Lei, et al.. (2016). LncRNAs: the bridge linking RNA and colorectal cancer. Oncotarget. 8(7). 12517–12532. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026